RN1201 injection for high-risk multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new cell therapy called RN1201 for people with a high-risk type of multiple myeloma. It’s designed to target two specific markers on myeloma cells (BCMA and CD19) and may be given after initial treatment to help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with multiple myeloma that has high-risk genetic features (like certain chromosome changes).
- You must have cancer cells that test positive for BCMA and/or CD19 markers.
- You must be at least 18 years old and generally healthy enough for treatment (ECOG score 0–2).
- You must have received no more than 4 rounds of your first treatment (induction therapy) and your cancer must have responded without getting worse.
- Your heart, kidneys, liver, lungs, and blood counts must be in adequate condition as shown by lab tests.
- You cannot have certain active infections, a history of severe autoimmune disease, or have had a stem cell transplant with ongoing graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
This early-stage trial tests a new therapy called RN9101 for multiple myeloma that has come back or stopped responding to previous treatments. The drug targets a specific protein (BCMA) on myeloma cells and may help patients whose disease has progressed despite earlier therapies.
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins on myeloma cells (BCMA and GPRC5D). It is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments.
Hear when a new Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.